About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:4439300
Allelic
Composition
Tg(CAG-lacZ,-SV40)#Bcv/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

reproductive system
• mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase
• tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations
• nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8)
• frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct

endocrine/exocrine glands
• mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase
• tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations
• nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8)
• frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas

mortality/aging
• recombinant adenoviruses Ad5CMVeGFP (AdGFP) or Ad5CMVCre (AdCre) are delivered to the ovarian surface epithelium (OSE) in vivo via intrabursal injection
• with a median survival of 113 days after injection
• decreased survival time in mice treated with exogenous 17beta-estradiol (E2) (50 vs. 113 days after AdCre)

neoplasm
• tumors from P4 treatment have a more diffuse pattern and a higher incidence of zellballen
• tumors from E2-treated mice display a more diffuse appearance, abundant surface papillae, and large areas of necrosis
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment
• E2 treatment accelerates tumor onset
• develop more tumors in the urogenital tissues (uterus, cervix, bladder, and urethra) after E2 treatment
• mice (9 of 11) develop large, well-vascularized ovarian tumors after intrabursal administration of adenovirus expressing Cre recombinase
• tumors have characteristics reflective of sex cord stromal tumors, including cysts and areas of cords or insular formations
• nascent tumors from the OSE layer, invading into the ovary 80-90 days after introduction of Cre recombinase (n=8)
• frequently (89%) accompanied by metastases to the diaphragm, liver, pancreas, spleen, intestines, body wall, uterus, and/or oviduct
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy
• some of the P4-treated mice that do not develop ovarian tumors die of tumors in the liver, spleen, and pancreas
• decreased incidence of ovarian neoplasms (64 vs. 82% in controls) in progesterone (P4)-treated mice (n=11)

homeostasis/metabolism
• peritoneal ascites with volumes ranging from 0.5-7.5 ml in 64% of the mice
• accumulation of ascites and adhesions in the abdomen in one mouse without ovarian tumor (out of 11 mice)
• E2 treatment decrease the incidence of peritoneal ascites accumulation

muscle
• one (in 11 mice) mouse die of tumors associated with the spleen, pancreas, liver, and diaphragm without ovarian tumors at necropsy

Mouse Models of Human Disease
OMIM ID Ref(s)
Ovarian Cancer 167000 J:158388


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
09/27/2016
MGI 6.05
The Jackson Laboratory